class="wp-theme-Newspaper supp-body td-standard-pack global-block-template-1 tdc-header-template tdc-footer-template td-animation-stack-type0 td-full-layout"
HORMONE-SENSITIVE CONDITIONS: Contraindicated in oestrogen receptor-positive (ER+) breast cancer, endometrial cancer, uterine fibroids, endometriosis — oestrogenic activity may stimulate tumour growth. Thyroid: may interfere with thyroid hormone synthesis — caution in hypothyroidism. Drug interaction: tamoxifen (may antagonise). Fertility: high doses may affect menstrual cycle. Male fertility: high doses may reduce testosterone.
Soy isoflavone with oestrogenic activity (phytoestrogen) — binds oestrogen receptors ERα and ERβ with preference for ERβ. Metabolised by gut bacteria to equol (more potent oestrogenic metabolite) in approximately 30-50% of people. Used for menopausal symptoms, bone health, and cardiovascular risk.
Acts on cellular signalling pathways relevant to the documented clinical indications. Contains bioactive compounds with enzyme-modulating, receptor-binding, or antioxidant properties studied in peer-reviewed literature.
| Population | Safety rating | Max safe dose |
|---|---|---|
| General | Possibly unsafe | — |
| Pregnancy | Possibly unsafe | — |
| Elderly | Possibly unsafe | — |
No peer-reviewed clinical trial data found for this ingredient.
Data by supplement.ge — Public Health Institute of Georgia (PHIG)